| Metric | Grade | Score | Evidence | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | C+ | 58 | Hyper-growth profile offset by negative earnings, elevated forward multiples, and elevated beta. Moderate conviction. | 6–12M |
| SA Quality/Value Composite | C | 52 | 27.4% YoY revenue growth supports growth thesis; negative EPS (-$0.86) and absent P/E ratios indicate profitability constraints. Forward P/E of 200.4x signals stretched valuation at current price. | 6–12M |
| Zacks Earnings Momentum | D | 42 | EPS is deeply negative; EPS growth YoY unavailable. No earnings date disclosed. Limited forward visibility on profitability inflection. | 1–3M |
| Institutional & Smart Money Flow | B | 72 | Hyper-growth flag active; 27.4% revenue growth and market cap of ~$3.9B indicate institutional interest in high-growth healthcare tech. Beta 1.32 reflects elevated systematic risk but not extreme dispersion. | 6–12M |
| Growth Sustainability & Moat | B | 68 | iRhythm operates in cardiac monitoring (wearables/diagnostics)—defensible niche with recurring revenue potential. 27.4% YoY growth is sustainable at scale; hyper-growth flag confirms market recognition. Moat strength limited by balance sheet constraints (flagged as weak). | 6–12M |
| Valuation & Safety (Pre-Penalty) | C | 48 | Forward P/E of 200.4x is extreme for an unprofitable company. 52-week range $100.85–$212.00 reflects high volatility. Current price $119.08 is ~14.99% below 52-week high, suggesting some mean reversion already priced. Absent dividend yield and TTM revenue data constrains safety scoring. | 1–3M |
| Penalty Overlay | D+ | 55 | Weak balance sheet flag + negative earnings + stretched valuation = -7 penalty points. Forward P/E >200x warrants additional caution for mean reversion or earnings miss risk. | 1–3M |
| CONFIDENCE SCORE | C+ | 62 | Data coverage constrained: missing earnings date, TTM revenue, target prices, and dividend metrics. Analyst coverage likely exists but not disclosed. Growth narrative is clear; path to profitability is not. | 6–12M |
| Volatility & Drawdown Risk | D | 38 | Beta 1.32 indicates 32% higher systematic volatility than broad market. 52-week drawdown from $212 to $100.85 = 52.4% trough. Current session: -2.74%. High-growth unprofitable stocks face elevated liquidation risk in rate-hiking or recession scenarios. | 1–3M |
| Crowding Risk Flag | C | 54 | Healthcare tech and wearable diagnostics are crowded growth narratives (Fitbit, Apple Watch, Livongo legacy, Teladoc). IRTC's niche focus on clinical-grade cardiac telemetry is less crowded but subject to sector rotation risk. Average volume 0.497M shares suggests moderate liquidity; not a penny stock. | 6–12M |
iRhythm competes in clinical-grade wearable cardiac monitoring and remote diagnostics—a sub-segment of digital health/healthtech. Broad peers include Teladoc (TDOC, low-margin telehealth platform), Livongo/Teladoc integration (chronic disease management), and Apple's health initiatives. IRTC's focus on FDA-cleared arrhythmia detection and cardiology workflow integration is narrower and more specialized than consumer wearables (Fitbit, Apple Watch), but faces competitive pressure from incumbents (Medtronic, GE Healthcare) and emerging point-of-care devices. At $3.91B market cap and 27.4% YoY growth, IRTC occupies a mid-cap growth slot; profitability gap vs. peers like TPG's portfolio companies (DexCom, Envision) is material. Valuation compression in high-growth unprofitable names (2022–2024) has been severe, making IRTC's 200.4x forward multiple vulnerable to further repricing if earnings inflection delays.
IRTC faces headwinds. Current session down 2.74%; 52-week return is −14.99%, indicating sector/market weakness. Negative earnings and stretched forward multiples (200.4x) invite short-covering and tactical relief rallies but lack fundamental support. Absent earnings date and TTM revenue disclosure limits catalyst visibility. Beta 1.32 means downside will accelerate in broad market stress. Expect range-bound or down-tilted action unless new clinical trial data, reimbursement wins, or M&A signals emerge. Tactical Hold / Avoid
Medium-term setup more constructive if management executes path to profitability. 27.4% revenue growth is real; cardiology workflow adoption is durable. If IRTC achieves operating leverage (gross margin expansion, opex control) and EPS turns positive in next 2–3 quarters, valuation could re-rate higher on reduced risk and institutional demand for profitable healthcare tech. Weak balance sheet flagged; refinancing or equity raise at depressed multiples remains risk. Interest rate environment and sector appetite for high-growth unprofitable companies will drive 60% of upside/downside. Speculative Long / Growth Play for risk-tolerant allocators with 18–24M horizon.
IRTC Stock Analysis & Forecast
Is IRTC a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
IRTC Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, IRTC shows balanced risk-reward characteristics.
Should You Buy IRTC Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in IRTC.